...All subjects had complete wound closure by day 35. No serious adverse events were reported. Glycotex...
...GLYC-101 significantly reduced time to complete wound closure vs. placebo (see BioCentury, April 13, 2009). Glycotex...
...the trial early due to undisclosed "logistical" reasons. Novogen owns an 81% stake in Glycotex. Glycotex Inc....

...respectively). Glycotex plans to enroll about 48 patients. Novogen owns an 81% stake in Glycotex. Glycotex Inc....

...A$0.56 on the Australian Stock Exchange and $0.08 to $1.85 on NASDAQ last week after Glycotex Inc....
...GLYC-101 topical gel is a topical application of glucoprime. Novogen owns an 81% stake in Glycotex...

...conducted after 26 subjects completed the double-blind, U.S. study of the topical application of glucoprime. Glycotex...
...to enroll about 48 patients. Novogen Ltd. (ASX:NRT; NASDAQ:NVGN), which owns an 81% stake in Glycotex...

...laser skin resurfacing on the lower eyelid area. Novogen owns an 81% stake in Glycotex. Glycotex Inc....

...placebo-controlled, U.S. Phase IIb trial of topical GLYC-101. Novogen owns an 81% stake in Glycotex. Glycotex Inc....

...Wound healing and tissue repair company Glycotex hired Reinhard Koenig as president, CEO and a director...
...and a director. Previously, Koenig was VP of clinical and product development at Questcor (QSC). Glycotex...

...CF) patients. Underwriters are Merrill Lynch; Morgan Stanley; and SG Cowen. On the downside, Australia's Glycotex...
...of Novogen (ASX:NRT; NVGN) said it plans to re-file for a public listing this year. Glycotex...

...and tissue repair product candidates. The company intends to re-file a registration statement this year. Glycotex's...
...III trial but could not say when it would start. In its S-1 in September, Glycotex...
...A $9 price would have raised $33.8 million and valued the company at $183.6 million. Glycotex...